Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...

Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion ...

Novo Nordisk is encouraged by White House proposals that could support patients using weight-loss drugs, but cautioned that ...

Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' ...

Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...

We came across a bullish thesis on Novo Nordisk A/S (NVO ... But with so many choices, how do you find the hidden gem – the company poised for explosive growth? That’s where our expertise ...

With the transactions stated above, Novo Nordisk A/S owns a total of 21,348,485 B shares of DKK 0.10, corresponding to 0.5% of the share capital, as treasury shares. The total number of A and B shares ...

The leading healthcare company specializing in diabetes care was honored with awards under the Inspirational Brand, Fast Enterprise, and Corporate Excellence categories. This remarkable feat not only ...

adding that the company is on track with answers to regulators’ questions on the deal. “I’m not worried about a plan B.” What Bloomberg Intelligence Says: Novo Nordisk’s 11% 3Q beat for obesity drug ...

and we are serving more patients than ever before,” Novo Nordisk CEO Lars Fruergaard Jørgensen said in a statement. Sales of the company’s weight loss drug Wegovy skyrocketed 79% to 17.3 ...

Despite the sales miss, Novo Nordisk's net income of DKK 27.3 billion came in higher than the DKK 26.66 billion analysts were expecting. Sales of the company's obesity and diabetes drugs jumped 25 ...